Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

DARPA Program Hits Milestone in Plant-Based Vaccines for Pandemics

by Global Biodefense Staff
July 28, 2012

In a recent milestone development under the Defense Advanced Research Project Agency (DARPA) “Blue Angel” program, researchers at Medicago Inc. produced more than 10 million doses of an H1N1 influenza vaccine candidate based on virus-like particles (VLP) in one month.

The Blue Angel program seeks to improve the nation’s ability to rapidly react to any natural or intentional pandemic disease. Program funding to Medicago was in support of developing new ways of producing large amounts of high-quality, vaccine-grade protein in less than three months in response to an outbreak.

This recent month-long “rapid fire” test displayed the potential for VLP vaccines to fill capability gaps of egg-based protein vaccine manufacturing during a crisis. The production lots adhered to Phase 1 current good manufacturing practices and were tested by a third party laboratory to confirm both the immunogenicity of the vaccine candidate and the number of doses produced.

“The results we’ve achieved here with plant-based production of vaccines represent both significant increase in scale and decrease in time-to-production over previous production capabilities in the same time period. The plant-made community is now better positioned to continue development and target FDA approval of candidate vaccines,” stated Dr. Alan Magill, DAPRA Program Manager. “Once the FDA has approved a plant-made vaccine candidate, the shorter production times of plant-made pharmaceuticals should allow DoD to be much better prepared to face whatever pandemic next emerges.”

To date, Medicago has received $19.8M in milestone payments from DARPA for this project, and expects to receive the fifth milestone payment of US $1M in the near future.

Tags: DARPAH1N1InfluenzaPandemicVaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC